Genelux
GNLXGenelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogen …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Genelux
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 3/2/2026 | Sell | Thomas, John | Director | $2.9 | $28,957 |
| 12/5/2025 | Sell | Smalling, Ralph | Head of Regulatory | $4.7 | $774 |
| 12/1/2025 | Sell | Thomas, John | Director | $5.0 | $50,008 |
| 11/17/2025 | Sell | Smalling, Ralph | Head of Regulatory | $5.4 | $1,842 |
| 11/17/2025 | Sell | Cappello, Joseph | Chief Technical Officer | $5.4 | $5,224 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)